Matches in SemOpenAlex for { <https://semopenalex.org/work/W5346711> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W5346711 endingPage "610" @default.
- W5346711 startingPage "610" @default.
- W5346711 abstract "610 Background: In our previous report, addition of bevacizumab (BV) to the FOLFOX4 regimen appeared to significantly improve response rate, progression-free survival and overall survival in first-line treatment for patients with metastatic colorectal cancer (mCRC) (Suenaga M, et al. ASCO-GI 2011 [abstr 588]). Update results met median overall survival, and statistical analysis of survival was performed. Methods: An observational cohort study was carried out on all eligible patients scheduled to receive FOLFOX4 (n = 128) or FOLFOX4+BV (n = 85) between 2005 and 2007, 2007 and 2009, with a median follow-up time of 20.4 months vs. 30.2 months, respectively. Predefined efficacy endpoints were treatment characteristics, response rates, progression-free survival, and overall survival in the periods of time observed. Results: Median progression-free survival was 9.9 months (95% CI, 8.4-11.4) in the FOLFOX4- and 17 months (95% CI, 11.8-22.3) in the FOLFOX4+BV-treated patients (p=0.002). Median overall survival times were 20.5 months (95% CI, 16.9-24) and 38.8 months (95% CI, 32.9-44.8) in the two groups, respectively (p<0.001). In the ECOG PS 0 population, progression-free survival in the FOLFOX4 and FOLFOX4+BV groups was 11 months and 17 months with a hazard ratio of 0.63 (95% CI, 0.44-0.89) in favour of FOLFOX4+BV, similarly in OS with a hazard ratio of 0.53 (95% CI, 0.36-0.77). Subgroup population received 5-FU plus leucovorin (FL) as maintenance during oxaliplatin discontinuation due to adverse events had longer PFS or OS in both groups, though no significance. PFS were 14.7 and 21.6 months, and OS were 29 and 45.9 months, respectively. Secondary resection was performed more in FOLFOX4+BV (11.8%) than FOLFOX4 (3.9%) patients. Conclusions: These data indicate potential survival benefits from the addition of BV to the FOLFOX4 regimen as first-line treatment for mCRC. Maintenance using FL after discontinuation of oxaliplatin due to adverse events appeared to be an essential factor for better survival." @default.
- W5346711 created "2016-06-24" @default.
- W5346711 creator A5020969371 @default.
- W5346711 creator A5021509769 @default.
- W5346711 creator A5031981364 @default.
- W5346711 creator A5038191750 @default.
- W5346711 creator A5066014367 @default.
- W5346711 creator A5069216249 @default.
- W5346711 creator A5069216523 @default.
- W5346711 creator A5077085235 @default.
- W5346711 creator A5078320729 @default.
- W5346711 date "2012-02-01" @default.
- W5346711 modified "2023-10-16" @default.
- W5346711 title "Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer." @default.
- W5346711 doi "https://doi.org/10.1200/jco.2012.30.4_suppl.610" @default.
- W5346711 hasPublicationYear "2012" @default.
- W5346711 type Work @default.
- W5346711 sameAs 5346711 @default.
- W5346711 citedByCount "0" @default.
- W5346711 crossrefType "journal-article" @default.
- W5346711 hasAuthorship W5346711A5020969371 @default.
- W5346711 hasAuthorship W5346711A5021509769 @default.
- W5346711 hasAuthorship W5346711A5031981364 @default.
- W5346711 hasAuthorship W5346711A5038191750 @default.
- W5346711 hasAuthorship W5346711A5066014367 @default.
- W5346711 hasAuthorship W5346711A5069216249 @default.
- W5346711 hasAuthorship W5346711A5069216523 @default.
- W5346711 hasAuthorship W5346711A5077085235 @default.
- W5346711 hasAuthorship W5346711A5078320729 @default.
- W5346711 hasConcept C121608353 @default.
- W5346711 hasConcept C126322002 @default.
- W5346711 hasConcept C143998085 @default.
- W5346711 hasConcept C207103383 @default.
- W5346711 hasConcept C2776694085 @default.
- W5346711 hasConcept C2777802072 @default.
- W5346711 hasConcept C2780739268 @default.
- W5346711 hasConcept C2781413609 @default.
- W5346711 hasConcept C2908647359 @default.
- W5346711 hasConcept C3019894029 @default.
- W5346711 hasConcept C44249647 @default.
- W5346711 hasConcept C526805850 @default.
- W5346711 hasConcept C71924100 @default.
- W5346711 hasConcept C72563966 @default.
- W5346711 hasConcept C90924648 @default.
- W5346711 hasConcept C99454951 @default.
- W5346711 hasConceptScore W5346711C121608353 @default.
- W5346711 hasConceptScore W5346711C126322002 @default.
- W5346711 hasConceptScore W5346711C143998085 @default.
- W5346711 hasConceptScore W5346711C207103383 @default.
- W5346711 hasConceptScore W5346711C2776694085 @default.
- W5346711 hasConceptScore W5346711C2777802072 @default.
- W5346711 hasConceptScore W5346711C2780739268 @default.
- W5346711 hasConceptScore W5346711C2781413609 @default.
- W5346711 hasConceptScore W5346711C2908647359 @default.
- W5346711 hasConceptScore W5346711C3019894029 @default.
- W5346711 hasConceptScore W5346711C44249647 @default.
- W5346711 hasConceptScore W5346711C526805850 @default.
- W5346711 hasConceptScore W5346711C71924100 @default.
- W5346711 hasConceptScore W5346711C72563966 @default.
- W5346711 hasConceptScore W5346711C90924648 @default.
- W5346711 hasConceptScore W5346711C99454951 @default.
- W5346711 hasIssue "4_suppl" @default.
- W5346711 hasLocation W53467111 @default.
- W5346711 hasOpenAccess W5346711 @default.
- W5346711 hasPrimaryLocation W53467111 @default.
- W5346711 hasRelatedWork W1963973664 @default.
- W5346711 hasRelatedWork W2080607747 @default.
- W5346711 hasRelatedWork W2107314204 @default.
- W5346711 hasRelatedWork W2325657449 @default.
- W5346711 hasRelatedWork W2517493814 @default.
- W5346711 hasRelatedWork W2745803145 @default.
- W5346711 hasRelatedWork W2947877747 @default.
- W5346711 hasRelatedWork W3004966710 @default.
- W5346711 hasRelatedWork W3206162654 @default.
- W5346711 hasRelatedWork W4253377742 @default.
- W5346711 hasVolume "30" @default.
- W5346711 isParatext "false" @default.
- W5346711 isRetracted "false" @default.
- W5346711 magId "5346711" @default.
- W5346711 workType "article" @default.